Status:
COMPLETED
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Lead Sponsor:
Amgen
Conditions:
Metastatic Colorectal Cancer
Skin Rash
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemothera...
Eligibility Criteria
Inclusion
- Patients with unresectable metastatic adenocarcinoma of the colon or rectum that cannot, in the opinion of the investigator, be cured by surgical resection at the time of randomization;
- Patients who have failed first line treatment containing fluoropyrimidine and oxaliplatin based chemotherapy with or without bevacizumab for mCRC.
Exclusion
- • Prior irinotecan use for the treatment of mCRC.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT00332163
Start Date
April 1 2006
End Date
September 1 2008
Last Update
February 23 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.